AAAAAA

   
Results: 1-11 |
Results: 11
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein, PHARM RES, 18(6), 2001, pp. 800-806
Inhibition of P-glycoprotein transport function by grapefruit juice psoralen
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Inhibition of P-glycoprotein transport function by grapefruit juice psoralen, PHARM RES, 18(4), 2001, pp. 432-438
In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes
Authors: Barecki, ME Casciano, CN Johnson, WW Clement, RP
Citation: Me. Barecki et al., In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes, DRUG META D, 29(9), 2001, pp. 1173-1175
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein, DRUG META D, 29(8), 2001, pp. 1080-1083
Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine
Authors: Palamanda, JR Casciano, CN Norton, LA Clement, RP Favreau, LV Lin, CC Nomeir, AA
Citation: Jr. Palamanda et al., Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine, DRUG META D, 29(6), 2001, pp. 863-867
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein, CANCER RES, 61(20), 2001, pp. 7525-7529
Active transport of fluorescent P-glycoprotein substrates: Evaluation as markers and interaction with inhibitors
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Active transport of fluorescent P-glycoprotein substrates: Evaluation as markers and interaction with inhibitors, BIOC BIOP R, 289(2), 2001, pp. 580-585
Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence, BBA-PROT ST, 1481(1), 2000, pp. 63-74
In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein, DRUG META D, 28(5), 2000, pp. 522-528
Cholesterol interaction with the daunorubicin binding site of P-glycoprotein
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Cholesterol interaction with the daunorubicin binding site of P-glycoprotein, BIOC BIOP R, 276(3), 2000, pp. 909-916
Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity
Authors: Wang, EJ Casciano, CN Clement, RP Johnson, WW
Citation: Ej. Wang et al., Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity, ARCH BIOCH, 383(1), 2000, pp. 91-98
Risultati: 1-11 |